Abstract
Mitochondrion is a semi-autonomous organelle, important for cell energy metabolism, apoptosis, the production of reactive oxygen species (ROS), and Ca2+ homeostasis. Mitochondrial DNA (mtDNA) mutation is one of the primary factors in mitochondrial disorders. Though much progress has been made, there remain many difficulties in constructing cell models for mitochondrial diseases. This seriously restricts studies related to targeted drug discovery and the mechanism and therapy for such diseases. Here we summarize the characteristics of patient-specific immortalized lymphoblastoid cells, fibroblastoid cells, cytoplasmic hybrid (cybrid) cell lines, and induced pluripotent stem cells (iPSCs)-derived differentiation cells in the study of mitochondrial disorders, as well as offering discussion of roles and advances of these cell models, particularly in the screening of drugs.
概 要
线粒体是一种半自主性细胞器, 不仅是细胞能量代谢的重要场所, 而且与细胞凋亡、 活性氧 (ROS) 产生和 Ca2+ 稳态等密切相关。 线粒体 DNA (mtDNA) 突变是线粒体疾病发生的重要原因。 当前, 线粒体疾病细胞模型构建仍存在许多困难, 严重制约线粒体疾病的致病机制、 靶向药物筛选和临床治疗等研究。 本文将重点介绍线粒体疾病细胞模型的构建和特征, 包括患者特异性永生化淋巴细胞模型、 成纤维细胞模型及其衍生的转线粒体细胞模型和诱导多能干细胞及其定向分化细胞模型, 以及这些细胞模型在线粒体药物筛选中的作用和研究进展。
Similar content being viewed by others
References
Aiyar RS, Bohnert M, Duvezin-Caubet S, et al., 2014. Mitochondrial protein sorting as a therapeutic target for ATP synthase disorders. Nat Commun, 5:5585. https://doi.org/10.1038/ncomms6585
Amoli MM, Carthy D, Platt H, et al., 2008. EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int J Epidemiol, 37(Suppl 1):i41–i45. https://doi.org/10.1093/ije/dym285
Barrow JJ, Balsa E, Verdeguer F, et al., 2016. Bromodomain inhibitors correct bioenergetic deficiency caused by mitochondrial disease complex I mutations. Mol Cell, 64(1): 163–175. https://doi.org/10.1016/j.molcel.2016.08.023
Boulting GL, Kiskinis E, Croft GF, et al., 2011. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol, 29(3):279–286. https://doi.org/10.1038/nbt.1783
Cámara Y, González-Vioque E, Scarpelli M, et al., 2014. Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome. Hum Mol Genet, 23(9):2459–2467. https://doi.org/10.1093/hmg/ddt641
Cherry ABC, Gagne KE, Mcloughlin EM, et al., 2013. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells, 31(7):1287–1297. https://doi.org/10.1002/stem.1354
Chin RM, Panavas T, Brown JM, et al., 2018. Patient-derived lymphoblastoid cell lines harboring mitochondrial DNA mutations as tool for small molecule drug discovery. BMC Res Notes, 11:205. https://doi.org/10.1186/s13104-018-3297-6
Chou SJ, Tseng WL, Chen CT, et al., 2016. Impaired ROS scavenging system in human induced pluripotent stem cells generated from patients with MERRF syndrome. Sci Rep, 6:23661. https://doi.org/10.1038/srep23661
Chou SJ, Ko YL, Yang YH, et al., 2018. Generation of two isogenic human induced pluripotent stem cell lines from a 15 year-old female patient with MERRF syndrome and A8344G mutation of mitochondrial DNA. Stem Cell Res, 30:201–205. https://doi.org/10.1016/j.scr.2018.05.011
Cotán D, Cordero MD, Garrido-Maraver J, et al., 2011. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J, 25(8):2669–2687. https://doi.org/10.1096/fj.10-165340
Couplan E, Aiyar RS, Kucharczyk R, et al., 2011. A yeast-based assay identifies drugs active against human mitochondrial disorders. Proc Natl Acad Sci USA, 108(29): 11989–11994. https://doi.org/10.1073/pnas.1101478108
de la Mata M, Garrido-Maraver J, Cotán D, et al., 2012. Recovery of MERRF fibroblasts and cybrids pathophysiology by coenzyme Q10. Neurotherapeutics, 9(2):446–463. https://doi.org/10.1007/s13311-012-0103-3
Ebert AD, Yu JY, Rose FF Jr, et al., 2009. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature, 457(7227):277–280. https://doi.org/10.1038/nature07677
Farrar GJ, Chadderton N, Kenna PF, et al., 2013. Mitochondrial disorders: aetiologies, models systems, and candidate therapies. Trends Genet, 29(8):488–497. https://doi.org/10.1016/j.tig.2013.05.005
Fujikura J, Nakao K, Sone M, et al., 2012. Induced pluripotent stem cells generated from diabetic patients with mitochondrial DNA A3243G mutation. Diabetologia, 55(6): 1689–1698. https://doi.org/10.1007/s00125-012-2508-2
Garrido-Maraver J, Cordero MD, Moñino ID, et al., 2012. Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease. Br J Pharmacol, 167(6):1311–1328. https://doi.org/10.1111/j.1476-5381.2012.02086.x
Holt IJ, Harding AE, Morgan-Hughes JA, 1988. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature, 331(6158):717–719. https://doi.org/10.1038/331717a0
Howlett EH, Jensen N, Belmonte F, et al., 2017. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Hum Mol Genet, 26(22):4340–4351. https://doi.org/10.1093/hmg/ddx320
Hsu YH, Wu YT, Huang CY, et al., 2017. Generation of an induced pluripotent stem cell line from a 39-year-old female patient with severe-to-profound non-syndromic sensorineural hearing loss and a A1555G mutation in the mitochondrial MTRNR1 gene. Stem Cell Res, 25:245–249. https://doi.org/10.1016/j.scr.2017.10.024
Inak G, Lorenz C, Lisowski P, et al., 2017. Concise review: induced pluripotent stem cell-based drug discovery for mitochondrial disease. Stem Cells, 35(7):1655–1662. https://doi.org/10.1002/stem.2637
Jeong MH, Kim JH, Seo KS, et al., 2014. β-Lapachone attenuates mitochondrial dysfunction in MELAS cybrid cells. Biochem Biophys Res Commun, 454(3):417–422. https://doi.org/10.1016/j.bbrc.2014.10.093
Jing R, Corbett JL, Cai J, et al., 2018. A screen using iPSC-derived hepatocytes reveals NAD+ as a potential treatment for mtDNA depletion syndrome. Cell Rep, 25(6): 1469–1484.e5. https://doi.org/10.1016/j.celrep.2018.10.036
Kang E, Wu J, Gutierrez NM, et al., 2016. Mitochondrial replacement in human oocytes carrying pathogenic mitochondrial DNA mutations. Nature, 540(7632):270–275. https://doi.org/10.1038/nature20592
Kang JF, Tang BS, Guo JF, 2016. The progress of induced pluripotent stem cells as models of Parkinson’s disease. Stem Cells Int, 2016:4126214. https://doi.org/10.1155/2016/4126214
Koopman WJH, Beyrath J, Fung CW, et al., 2016. Mitochondrial disorders in children: toward development of small-molecule treatment strategies. EMBO Mol Med, 8(4):311–327. https://doi.org/10.15252/emmm.201506131
Li SS, Pan HY, Tan C, et al., 2018. Mitochondrial dysfunctions contribute to hypertrophic cardiomyopathy in patient iPSC-derived cardiomyocytes with MT-RNR2 mutation. Stem Cell Reports, 10(3):808–821. https://doi.org/10.1016/j.stemcr.2018.01.013
Lorenz C, Lesimple P, Bukowiecki R, et al., 2017. Human iPSC-derived neural progenitors are an effective drug discovery model for neurological mtDNA disorders. Cell Stem Cell, 20(5):659–674.e9. https://doi.org/10.1016/j.stem.2016.12.013
Lu HE, Yang YP, Chen YT, et al., 2018. Generation of patient-specific induced pluripotent stem cells from Leber’s hereditary optic neuropathy. Stem Cell Res, 28:56–60. https://doi.org/10.1016/j.scr.2018.01.029
Ma H, Folmes CDL, Wu J, et al., 2015. Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature, 524(7564):234–238. https://doi.org/10.1038/nature14546
Matsubara M, Kanda H, Imamura H, et al., 2018. Analysis of mitochondrial function in human induced pluripotent stem cells from patients with mitochondrial diabetes due to the A3243G mutation. Sci Rep, 8(1):949. https://doi.org/10.1038/s41598-018-19264-7
Mattiazzi M, Vijayvergiya C, Gajewski CD, et al., 2004. The mtDNA T8993G (NARP) mutation results in an impairment of oxidative phosphorylation that can be improved by antioxidants. Hum Mol Genet, 13(8):869–879. https://doi.org/10.1093/hmg/ddh103
Pfeffer G, Horvath R, Klopstock T, et al., 2013. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol, 9(8):474–481. https://doi.org/10.1038/nrneurol.2013.129
Reardon S, 2016. Reports of ‘three-parent babies’ multiply. Nature News [Accessed on Apr. 11, 2019]. https://doi.org/10.1038/nature.2016.20849
Saada A, 2011. The use of individual patient’s fibroblasts in the search for personalized treatment of nuclear encoded OXPHOS diseases. Mol Genet Metab, 104(1–2):39–47. https://doi.org/10.1016/j.ymgme.2011.07.016
Sala L, Bellin M, Mummery CL, 2017. Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come? Br J Pharmacol, 174(21):3749–3765. https://doi.org/10.1111/bph.13577
Sun JJ, Zhao XX, Qiao LH, et al., 2016. Cellular models for mitochondrial DNA-based diseases: lymphoblastoid cell lines and transmitochondrial cybrids. Hereditas (Beijing), 38(7):666–673 (in Chinese). https://doi.org/10.162887j.yczz.16-085
Wallace DC, 2013. A mitochondrial bioenergetic etiology of disease. J Clin Invest, 123(4):1405–1412. https://doi.org/10.1172/JCI61398
Wallace DC, Fan WW, 2009. The pathophysiology of mitochondrial disease as modeled in the mouse. Genes Dev, 23(15):1714–1736. https://doi.org/10.1101/gad.1784909
Wallace DC, Singh G, Lott MT, et al., 1988. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science, 242(4884):1427–1430. https://doi.org/10.1126/science.3201231
Wilkins HM, Carl SM, Swerdlow RH, 2014. Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biol, 2:619–631. https://doi.org/10.1016/j.redox.2014.03.006
Wu J, Ocampo A, Belmonte JCI, 2016. Cellular metabolism and induced pluripotency. Cell, 166(6):1371–1385. https://doi.org/10.1016/j.cell.2016.08.008
Wu YR, Wang AG, Chen YT, et al., 2018. Bioactivity and gene expression profiles of hiPSC-generated retinal ganglion cells in MT-ND4 mutated Leber’s hereditary optic neuropathy. Exp Cell Res, 363(2):299–309. https://doi.org/10.1016/j.yexcr.2018.01.020
Yamanaka S, 2007. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell, 1(1):39–49. https://doi.org/10.1016/j.stem.2007.05.012
Yan QF, Guan MX, 2008. Nuclear genes and mitochondrial genes associated with mitochondrial diseases. Chin Bull Life Sci, 20(4):497–505 (in Chinese). https://doi.org/10.3969/j.issn.1004-0374.2008.04.002
Acknowledgments
We thank Chris WOOD of the College of Life Sciences Zhejiang University (Hangzhou, China) for checking the English of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Project supported by the National Basic Research Program of China (No. 2014CB943001), the National Natural Science Foundation of China (Nos. 31771398 and 31571299), the Fundamental Research Funds for the Central Universities (No. 2019QNA6001), and the Zhejiang Provincial Natural Science Foundation of China (Nos. LZ19C060001 and LY14C060004)
Rights and permissions
About this article
Cite this article
Hu, Sy., Zhuang, Qq., Qiu, Y. et al. Cell models and drug discovery for mitochondrial diseases. J. Zhejiang Univ. Sci. B 20, 449–456 (2019). https://doi.org/10.1631/jzus.B1900196
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B1900196